뒤로
NRX Pharmaceuticals Inc(NRXP) 가격
NRXP 주가 차트
NRXP 수입
NRX Pharmaceuticals Inc
$2.27
5.58%
$0.12
종가: Jan 16, 16:00:00 GMT-5
$2.27
0%
$0
애프터마켓: Jan 16, 20:00:00 GMT-5
최신 수익 결과: Q3 '25
보고됨: 2025-11-14
역사적 수익
분기별
연간
EPS
수익
Earnings FAQ
NRXP의 최근 주당순이익(EPS)은 예상과 비교하여 어떤가요?
NRX Pharmaceuticals Inc NRXP의 지난 분기 매출 실적은 어땠나요?
NRX Pharmaceuticals Inc의 매출 추정치는 얼마인가요?
NRX Pharmaceuticals Inc의 수익 품질 점수는 얼마인가요?
NRX Pharmaceuticals Inc는 언제 수익을 보고하나요?
NRX Pharmaceuticals Inc의 예상 수익은 얼마인가요?
NRX Pharmaceuticals Inc은 수익 기대치를 충족했나요?
주요 통계
이전 종가
$2.15
시가
$2.18
일일 범위
$2.15 - $2.38
52주 범위
$1.58 - $4.27
거래량
1.5M
평균 거래량
862.1K
EPS(TTM)
-2.32
배당수익률
--
시가총액
$63.7M
NRXP란 무엇인가요?
NRX Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company is headquartered in Wilmington, Delaware. The company went IPO on 2017-11-20. The company is developing NRX-100 (preservative-free intravenous ketamine) and NRX-101, (oral D-cycloserine/lurasidone). NRX-100 has been awarded Fast Track Designation for the treatment of Suicidal Ideation in Depression, including Bipolar Depression. NRX-101 has been awarded Breakthrough Therapy Designation for the treatment of suicidal bipolar depression. NRx has filed an Abbreviated New Drug Application (ANDA) and initiated a New Drug Application filing for NRX-100 (IV ketamine) with an application for the Commissioner’s National Priority Voucher Program for the treatment of suicidal depression. Its subsidiary, HOPE Therapeutics, Inc., is a healthcare delivery company that is building a network of interventional psychiatry clinics.